BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 10410146)

  • 1. [Effects of DAC (doxifluridine, adriamycin, cyclophosphamide) chemotherapy in advanced breast cancer patients].
    Tashiro H; Takahashi I; Yamamura S; Ishikawa T; Yanaga K; Wakasugi K; Matsusaka T; Kume K
    Gan To Kagaku Ryoho; 1999 May; 26(6):775-9. PubMed ID: 10410146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Combined chemoendocrine therapy using adriamycin, cyclophosphamide and high dose toremifene in patients with recurrent breast cancer].
    Wada N; Kobayashi H; Oka S; Ando J; Tamura H
    Gan To Kagaku Ryoho; 2002 Nov; 29(11):1935-42. PubMed ID: 12465393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A randomized controlled study of (2'' R)-4'-O-tetrahydropyranyladriamycin and adriamycin in combination with cyclophosphamide and 5-fluorouracil in the treatment of advanced and recurrent breast cancer].
    Abe O; Tominaga T; Enomoto K; Abe R; Iino Y; Koyama H; Fujimoto M; Nomura Y; Tanaka T
    Gan To Kagaku Ryoho; 1986 Jun; 13(6):2160-8. PubMed ID: 3717960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical evaluation of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) on advanced and recurrent breast cancer. Clinical study group of CMF for breast cancer in Japan].
    Nomura Y; Tominaga T; Adachi I; Koyama H; Fukami A
    Gan To Kagaku Ryoho; 1994 Sep; 21(12):1949-56. PubMed ID: 8085846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combination chemotherapy of cyclophosphamide adriamycin and 5-fluorouracil (CAF) in advanced and recurrent breast cancer].
    Abe O; Izuo M; Enomoto K; Kubo K; Koyama H; Sakai K; Terasawa T; Tominaga T; Nomura Y
    Gan To Kagaku Ryoho; 1982 May; 9(5):866-73. PubMed ID: 7184431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapeutic efficacy of pirarubicin cyclophosphamide and doxifluridine in advanced and metastatic breast cancer].
    Inoue K; Tabei T; Suemasu K; Higashi Y; Kurosumi M
    Gan To Kagaku Ryoho; 1999 Apr; 26(5):637-42. PubMed ID: 10234294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
    Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of combination therapy consisting of cyclophosphamide, adriamycin, UFT and oophorectomy/tamoxifen for advanced or recurrent breast cancer].
    Kiman K; Suzuki S; Satomi T; Sakonji M; Nihei M; Tanaka T; Kimijima I; Abe R
    Gan To Kagaku Ryoho; 1994 Oct; 21(14):2445-52. PubMed ID: 7944490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
    Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
    J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The feasibility of CEF (cyclophosphamide, epirubicin, 5-FU) regimen in the adjuvant setting of primary breast cancer].
    Honda S; Toi M; Shimizu S; Hayashi K; Tominaga T
    Gan To Kagaku Ryoho; 1997 Apr; 24(6):679-83. PubMed ID: 9126304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A double-blind randomized comparative study of oral 5-fluorouracil (5-FU), cyclophosphamide (CPA), and 5-FU + CPA in advanced breast cancer].
    Takayama T; Nomura Y
    Gan To Kagaku Ryoho; 2000 Jan; 27(1):73-80. PubMed ID: 10660736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combination chemotherapy using cyclophosphamide, adriamycin, and cisplatin in recurrent or advanced endometrial cancer--a preliminary report].
    Baba S; Kashimura M; Shinohara M; Kusano S; Sasayama T; Hamasaki K
    Gan No Rinsho; 1989 Feb; 35(3):371-7. PubMed ID: 2926985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vinorelbine and 5-fluorouracil bolus and/or continuous venous infusion plus levofolinic acid as second-line chemotherapy for metastatic breast cancer: an analysis of results in clinical practice of the Gruppo Oncologico Italia Meridionale (GOIM).
    Gebbia V; Caruso M; Borsellino N; Ajello R; Tirrito ML; Chiarenza M; Valenza R; Verderame F; Varvara F; Marrazzo A; Bajardi E; Ferrao F; Bordonaro R; Tralongo P
    Anticancer Res; 2006; 26(4B):3143-50. PubMed ID: 16886648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical evaluation of adriamycin in advanced and recurrent breast cancer (No. 4)--Joint study by 30 institutes on the duration of remission using various maintenance therapies in patients treated with CAF. Clinical Study Group of Adriamycin for Breast Cancer in Japan].
    Nomura Y; Abe O; Izuo M; Inoue K; Enomoto K; Kubo K; Koyama H; Sakai K; Terasawa T; Tominaga T
    Gan To Kagaku Ryoho; 1988 Jun; 15(6):1863-71. PubMed ID: 3382238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A study of combined chemotherapy with MMC, ADM, CDDP, etoposide (VP-16), 5'DFUR (MAC-VD therapy) in advanced cancer and local relapse of the stomach].
    Yasutake K; Imamura Y; Yoshimura Y; Oya M; Matsushita K; Tokisue M; Ohno S; Masuda T
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):397-401. PubMed ID: 2138004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The clinical efficacy of CAC regimen in the treatment of advanced breast cancer].
    Zhang P; Zhou J; Feng F
    Zhonghua Zhong Liu Za Zhi; 1995 Sep; 17(5):365-7. PubMed ID: 8697977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy with vinorelbine, cisplatin and continuous infusion of 5-fluorouracil in locally advanced breast cancer: a promising low-toxic regimen.
    Orlando L; Colleoni M; Curigliano G; Nolè F; Ferretti G; Masci G; Peruzzotti G; Minchella I; Intra M; Veronesi P; Viale G; Goldhirsch A
    Anticancer Res; 2001; 21(6A):4135-9. PubMed ID: 11911307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Results of clinical study with epirubicin hydrochloride injectable solution and cyclophosphamide in breast cancer].
    Koyama H; Adachi I; Tajima T; Kanda K; Yoshida M; Miura S; Nakao K; Kikkawa N; Takai S; Toge T; Tamura K; Inaji H; Shiba E
    Gan To Kagaku Ryoho; 1998 Sep; 25(11):1721-9. PubMed ID: 9757198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Results of clinical trials with a CMitF (cyclophosphamide, mitoxantrone, and 5-fluorouracil) regimen versus a CAF (cyclophosphamide, adriamycin, and 5-fluorouracil) regimen in advanced/relapsed breast cancer].
    Taguchi T; Sakai K; Terasawa T; Wada H
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2820-8. PubMed ID: 3530139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical evaluation of adriamycin for advanced breast cancer (3)--a joint study by 26 institutes on the CAF and CMcF treatment].
    Kubo K; Abe O; Izuo M; Enomoto K; Koyama H; Sakai K; Terasawa T; Tominaga T; Nomura Y
    Gan To Kagaku Ryoho; 1983 Dec; 10(12):2523-31. PubMed ID: 6689117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.